What is Immix Biopharma Inc's earnings per share (EPS)?

Immix Biopharma Inc (IMMX) reported diluted earnings per share of $-0.89 for fiscal year 2025. This represents a -17.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Immix Biopharma Inc Financials

IMMX

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Immix Biopharma Inc (IMMX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 40/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Immix Biopharma Inc has an operating margin of -149.8%, meaning the company retains $-150 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

100

Immix Biopharma Inc carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.01, Immix Biopharma Inc holds $10.01 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Immix Biopharma Inc generated -$23.9M in operating cash flow, capex of $733K consumed most of it, leaving -$24.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Immix Biopharma Inc generates a -31.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -163.1% the prior year.

Piotroski F-Score Weak

3/9

Immix Biopharma Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Immix Biopharma Inc generates $0.81 in operating cash flow (-$23.9M OCF vs -$29.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.0M

Immix Biopharma Inc generated $20.0M in revenue in fiscal year 2025.

EBITDA

-$29.6M

YoY-31.2%

Immix Biopharma Inc's EBITDA was -$29.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.2% from the prior year.

Net Income

-$29.4M

YoY-36.2%

Immix Biopharma Inc reported -$29.4M in net income in fiscal year 2025. This represents a decrease of 36.2% from the prior year.

EPS (Diluted)

$-0.89

YoY-17.1%

Immix Biopharma Inc earned $-0.89 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 17.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$24.7M

YoY-56.4%

Immix Biopharma Inc generated -$24.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 56.4% from the prior year.

Cash & Debt

$93.9M

YoY+431.2%

5Y CAGR+199.3%

Immix Biopharma Inc held $93.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

53M

YoY+92.3%

Immix Biopharma Inc had 53M shares outstanding in fiscal year 2025. This represents an increase of 92.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-149.8%

Immix Biopharma Inc's operating margin was -149.8% in fiscal year 2025, reflecting core business profitability.

Net Margin

-147.2%

Immix Biopharma Inc's net profit margin was -147.2% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-31.4%

YoY+131.7pp

Immix Biopharma Inc's ROE was -31.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 131.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$16.3M

YoY+44.0%

5Y CAGR+130.8%

Immix Biopharma Inc invested $16.3M in research and development in fiscal year 2025. This represents an increase of 44.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$733K

YoY-37.8%

Immix Biopharma Inc invested $733K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 37.8% from the prior year.

IMMX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$20.0M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16.3M+44.0%	$11.3M+29.3%	$8.7M+108.2%	$4.2M+3216.1%	$127K-49.0%	$248K
SG&A Expenses	$13.7M+20.3%	$11.4M+53.7%	$7.4M+84.1%	$4.0M+228.3%	$1.2M+495.8%	$206K
Operating Income	-$30.0M-32.1%	-$22.7M-40.5%	-$16.1M-96.4%	-$8.2M-507.9%	-$1.4M-197.9%	-$454K
Interest Expense	N/A	N/A	N/A	$497-99.7%	$180K+76.4%	$102K
Income Tax	$38K-8.1%	$41K+55.4%	$26K+157.3%	$10K+70.8%	$6K-65.7%	$18K
Net Income	-$29.4M-36.2%	-$21.6M-40.1%	-$15.4M-87.4%	-$8.2M+66.2%	-$24.4M-2024.3%	-$1.1M
EPS (Diluted)	$-0.89-17.1%	$-0.76+14.6%	$-0.89-50.8%	$-0.59	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.6M+15.4%	$4.0M+101.1%	$2.0M	N/A	$4.4M+99.9%	$2.2M-31.5%	$3.2M	N/A
SG&A Expenses	$3.1M+12.1%	$2.7M+1.4%	$2.7M	N/A	$2.9M+19.0%	$2.5M+5.8%	$2.3M	N/A
Operating Income	-$7.7M-14.1%	-$6.7M-43.5%	-$4.7M	N/A	-$7.4M-57.3%	-$4.7M+15.9%	-$5.6M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$8K-13.4%	$9K-9.2%	$10K	N/A	$11K+8.5%	$10K+16.2%	$9K	N/A
Net Income	-$7.6M-14.5%	-$6.6M-45.8%	-$4.5M	N/A	-$7.1M-62.7%	-$4.4M+16.5%	-$5.3M	N/A
EPS (Diluted)	$-0.24-9.1%	$-0.22-46.7%	$-0.15	N/A	$-0.24-60.0%	$-0.15+31.8%	$-0.22	N/A

IMMX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$104.8M+356.9%	$22.9M+15.2%	$19.9M+33.7%	$14.9M-18.1%	$18.2M+3271.4%	$540K
Current Assets	$101.2M+401.2%	$20.2M+2.1%	$19.8M+32.8%	$14.9M-18.1%	$18.2M+3317.0%	$532K
Cash & Equivalents	$93.9M+431.2%	$17.7M+1.0%	$17.5M+30.3%	$13.4M-23.8%	$17.6M+4411.7%	$391K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.0M+13.9%	$9.7M+160.5%	$3.7M+112.9%	$1.7M+765.3%	$202K-96.2%	$5.3M
Current Liabilities	$10.1M+16.4%	$8.7M+133.4%	$3.7M+192.3%	$1.3M+530.2%	$202K-96.2%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$93.8M+607.8%	$13.3M-19.2%	$16.4M+24.7%	$13.2M-26.8%	$18.0M+480.3%	-$4.7M
Retained Earnings	-$104.5M-39.2%	-$75.0M-40.5%	-$53.4M-40.6%	-$38.0M-27.7%	-$29.8M-453.9%	-$5.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$20.1M+28.4%	$15.6M-21.4%	$19.9M-13.3%	$22.9M-8.7%	$25.1M-12.8%	$28.8M-16.0%	$34.3M+72.4%	$19.9M
Current Assets	$16.6M+34.6%	$12.3M-26.5%	$16.8M-16.9%	$20.2M-11.2%	$22.8M-16.7%	$27.3M-17.0%	$32.9M+66.3%	$19.8M
Cash & Equivalents	$15.9M+37.0%	$11.6M-26.9%	$15.9M-10.0%	$17.7M-10.2%	$19.7M-17.9%	$24.0M-18.2%	$29.3M+67.4%	$17.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.8M+7.6%	$11.0M+6.6%	$10.3M+6.2%	$9.7M+27.7%	$7.6M+53.5%	$4.9M-26.4%	$6.7M+80.4%	$3.7M
Current Liabilities	$10.9M+8.4%	$10.0M+7.5%	$9.3M+7.1%	$8.7M+32.3%	$6.6M+68.2%	$3.9M-31.0%	$5.7M+52.0%	$3.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M+77.6%	$4.7M-51.5%	$9.6M-27.6%	$13.3M-24.5%	$17.6M-26.5%	$23.9M-14.4%	$27.9M+70.2%	$16.4M
Retained Earnings	-$93.8M-8.8%	-$86.2M-8.3%	-$79.6M-6.1%	-$75.0M-6.9%	-$70.2M-11.3%	-$63.1M-7.5%	-$58.7M-9.8%	-$53.4M

IMMX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$23.9M-64.0%	-$14.6M-28.3%	-$11.4M-53.5%	-$7.4M-366.1%	-$1.6M-292.7%	-$405K
Capital Expenditures	$733K-37.8%	$1.2M+2160.9%	$52K	N/A	$802	N/A
Free Cash Flow	-$24.7M-56.4%	-$15.8M-38.1%	-$11.4M	N/A	-$1.6M	N/A
Investing Cash Flow	-$7.2M-512.5%	-$1.2M-2160.9%	-$52K	N/A	-$802	N/A
Financing Cash Flow	$107.4M+573.3%	$15.9M+3.1%	$15.5M+378.4%	$3.2M-82.9%	$18.8M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$100K	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$5.9M-11.2%	-$5.3M-215.1%	-$1.7M-14.2%	-$1.5M+63.4%	-$4.0M+23.2%	-$5.3M-37.3%	-$3.8M-42.9%	-$2.7M
Capital Expenditures	$372K+191.8%	$128K+88.5%	$68K-86.6%	$507K+86.8%	$272K+179.7%	$97K-67.8%	$302K+2191.2%	$13K
Free Cash Flow	-$6.3M-15.5%	-$5.4M-210.2%	-$1.8M+11.6%	-$2.0M+54.0%	-$4.3M+19.5%	-$5.4M-29.7%	-$4.1M-53.5%	-$2.7M
Investing Cash Flow	-$372K-191.8%	-$128K-88.5%	-$68K+86.6%	-$507K-86.8%	-$272K-179.7%	-$97K+67.8%	-$302K-2191.2%	-$13K
Financing Cash Flow	$10.6M	N/A	N/A	$0	$0	$0-100.0%	$15.9M+2618.4%	$587K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMMX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-149.8%	N/A	N/A	N/A	N/A	N/A
Net Margin	-147.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-31.4%+131.7pp	-163.1%-69.1pp	-94.0%-31.5pp	-62.5%+73.0pp	-135.5%	N/A
Return on Assets	-28.1%+66.1pp	-94.2%-16.8pp	-77.4%-22.2pp	-55.2%+78.8pp	-134.0%+78.7pp	-212.7%
Current Ratio	10.01+7.7	2.33-3.0	5.32-6.4	11.70-78.3	90.01+89.9	0.10
Debt-to-Equity	0.12-0.6	0.73+0.5	0.23+0.1	0.13+0.1	0.01+1.1	-1.11
FCF Margin	-123.3%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-91.8%+50.6pp	-142.3%-95.0pp	-47.3%	N/A	-40.7%-22.3pp	-18.4%+0.5pp	-18.8%	N/A
Return on Assets	-37.8%+4.6pp	-42.4%-19.5pp	-22.8%	N/A	-28.4%-13.2pp	-15.2%+0.1pp	-15.3%	N/A
Current Ratio	1.53+0.3	1.23-0.6	1.80-0.5	2.33-1.1	3.47-3.5	7.00+1.2	5.82+0.5	5.32
Debt-to-Equity	1.43-0.9	2.36+1.3	1.07+0.3	0.73+0.3	0.43+0.2	0.21-0.0	0.24+0.0	0.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Igm Biosciences, Inc. IGMS

$76.6M

Beyondspring Inc BYSI

$67.4M

Adicet Bio Inc ACET

$65.4M

OS THERAPIES INCORPORATED OSTX

$49.7M

Nrx Pharmaceuticals Inc NRXP

$70.4M

Frequently Asked Questions

What is Immix Biopharma Inc's annual revenue?

Immix Biopharma Inc (IMMX) reported $20.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Immix Biopharma Inc profitable?

No, Immix Biopharma Inc (IMMX) reported a net income of -$29.4M in fiscal year 2025, with a net profit margin of -147.2%.

What is Immix Biopharma Inc's EBITDA?

Immix Biopharma Inc (IMMX) had EBITDA of -$29.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Immix Biopharma Inc's operating margin?

Immix Biopharma Inc (IMMX) had an operating margin of -149.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Immix Biopharma Inc's net profit margin?

Immix Biopharma Inc (IMMX) had a net profit margin of -147.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Immix Biopharma Inc's return on equity (ROE)?

Immix Biopharma Inc (IMMX) has a return on equity of -31.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Immix Biopharma Inc's free cash flow?

Immix Biopharma Inc (IMMX) generated -$24.7M in free cash flow during fiscal year 2025. This represents a -56.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Immix Biopharma Inc's operating cash flow?

Immix Biopharma Inc (IMMX) generated -$23.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Immix Biopharma Inc's total assets?

Immix Biopharma Inc (IMMX) had $104.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Immix Biopharma Inc's capital expenditures?

Immix Biopharma Inc (IMMX) invested $733K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Immix Biopharma Inc spend on research and development?

Immix Biopharma Inc (IMMX) invested $16.3M in research and development during fiscal year 2025.

How many shares does Immix Biopharma Inc have outstanding?

Immix Biopharma Inc (IMMX) had 53M shares outstanding as of fiscal year 2025.

What is Immix Biopharma Inc's current ratio?

Immix Biopharma Inc (IMMX) had a current ratio of 10.01 as of fiscal year 2025, which is generally considered healthy.

What is Immix Biopharma Inc's debt-to-equity ratio?

Immix Biopharma Inc (IMMX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Immix Biopharma Inc's return on assets (ROA)?

Immix Biopharma Inc (IMMX) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Immix Biopharma Inc's cash runway?

Based on fiscal year 2025 data, Immix Biopharma Inc (IMMX) had $93.9M in cash against an annual operating cash burn of $23.9M. This gives an estimated cash runway of approximately 47 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Immix Biopharma Inc's Piotroski F-Score?

Immix Biopharma Inc (IMMX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Immix Biopharma Inc's earnings high quality?

Immix Biopharma Inc (IMMX) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Immix Biopharma Inc?

Immix Biopharma Inc (IMMX) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.